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Sizing nanomaterials in complex biological ﬂuids, such as blood, remains a great challenge in
spite of its importance for a wide range of biomedical applications. In drug delivery, for
instance, it is essential that aggregation of protein-based drugs is avoided as it may alter their
efﬁcacy or elicit immune responses. Similarly it is of interest to determine which size of
molecules can pass through biological barriers in vivo to diagnose pathologies, such as sepsis.
Here, we report on continuous ﬂuorescence recovery after photobleaching (cFRAP) as a
analytical method enabling size distribution measurements of nanomaterials (1–100 nm)
in undiluted biological ﬂuids. We demonstrate that cFRAP allows to measure protein
aggregation in human serum and to determine the permeability of intestinal and vascular
barriers in vivo. cFRAP is a new analytical technique that paves the way towards exciting new
applications that beneﬁt from nanomaterial sizing in bio-ﬂuids.
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M
easuring the size of nanosized materials in complex
biological ﬂuids, such as blood or cerebrospinal ﬂuid, is
of great importance in a wide range of applications
in the life sciences. In drug delivery, for instance, the effective
size of nanomaterials in bio-ﬂuids is important because it directly
inﬂuences the biodistribution in the body1–4. Indeed, even though
nanomedicine formulations may be stable under normal
storage conditions, they may very well aggregate after
administration into a biological ﬂuid such as blood5,6. Similarly,
there is a growing appreciation that the colloidal stability of
therapeutic proteins needs to be tested in blood as protein
aggregation after intravenous administration will alter their
functionality and may induce immunogenic responses7,8. Yet,
methods to investigate submicron protein aggregates in serum are
virtually non-existent9,10. Being able to size nanomaterials in
bio-ﬂuids is of interest to medical diagnosis as well, for
instance to determine intestinal or vascular barrier permeability
which is related to several pathologies, such as sepsis, liver
disease, inﬂammatory bowel disease and neurodegenerative
diseases11–13. Barrier permeability can be assessed by
administering inert size probes, for example, orally or
intravenously, followed by quantiﬁcation of the size and
amount of probes that have leaked through the barrier.
Despite its relevance, measuring the size of molecules and
nanomaterials in complex biological ﬂuids remains a major
challenge. A few years ago our group demonstrated that
nanoparticles can be sized in undiluted biological ﬂuids by
ﬂuorescence single particle tracking microscopy14–17. However,
as it is based on imaging the Brownian motion of individual,
ﬂuorescently labelled nanomaterials, it is mostly suited for
nanoparticles with a size above B0.1mm. Therefore, a technique
for measuring size distributions of nanomaterials in bio-ﬂuids in
the 1–100 nm range is still very much needed.
Here we report on the use of ﬂuorescence recovery after
photobleaching (FRAP) to measure size distributions of
nanomaterials in biological ﬂuids. In a FRAP experiment, the
sample is placed on a confocal laser scanning microscope and
the ﬂuorescently labelled molecules or nanoparticles are
photobleached in a micron sized area by a powerful excitation
pulse. The ﬂuorescence inside the bleach area will subsequently
recover at a rate that is proportional to the diffusional rate of the
ﬂuorescent species. Until now, FRAP data have mostly been
analysed and interpreted in terms of a single average diffusion
coefﬁcient. Verkman and Periasamy18 were the ﬁrst to develop a
FRAP model for the measurement of continuous distributions of
diffusion coefﬁcients. The method was based on measuring the
ﬂuorescence intensity as a function of time in a spot bleached by a
stationary focused laser beam, as was common at that time.
Consequently, since only time information was taken into
account, the resolution to discriminate species with a different
diffusion coefﬁcient was rather limited (factor of 8). A similar
approach was recently reported based on multi-photon spot
beaching experiments for determining the size of macromolecular
complexes in cells19. In the meantime, Hauser et al.20 showed that
the resolution to discriminate two diffusing components could
be substantially enhanced (factor of 3) by including spatial
information into FRAP analysis. Building forth on these concepts,
here we propose an improved FRAP methodology that enables
the measurement of continuous distributions of diffusion
coefﬁcients (cFRAP), which can be easily converted to
equivalent size distributions. A rectangle is photobleached and
the full tempo-spatial information available in the confocal
recovery images is exploited using a dedicated theoretical
recovery model to extract a continuous distribution of diffusion
coefﬁcients. The method is very ﬂexible in that the rectangle can
have any size, which conveniently allows to optimize the recovery
time for a given diffusion coefﬁcient so as to optimally match the
sampling rate of the microscope used.
Following detailed validation of the cFRAP-sizing approach,
we demonstrate its strength and versatility in a number of
challenging sizing applications. First we demonstrate that
cFRAP-sizing enables accurate determination of protein
aggregation in undiluted blood serum. Next, in combination
with the administration of a broad range of inert size probes, we
show that cFRAP-sizing allows to characterize in great detail the
intestinal and vascular permeability in mice. Importantly, since a
single measurement is sufﬁcient to determine the full-size
distribution of probes that have leaked through the barrier, we
ﬁnd that the number of animals needed to assess the barrier
permeability is reduced up to ﬁve times compared with classic
approaches where probes of different size are administered and
analysed separately.
Results
Validation of cFRAP-sizing. The cFRAP method that we
propose is based on the photobleaching of a rectangular area
(Fig. 1 and Supplementary Fig. 1). A time-lapse confocal image
series is recorded after photobleaching to capture the ﬂuorescence
recovery due to diffusion. A closed-form analytical model
describing continuous diffusion in such a bleached rectangle
(see the ‘Methods’ section) is ﬁtted in a least-squares sense to this
three-dimensional (3D) data set (two-dimensional (2D) spatial
þ 1-D temporal) under condition of maximum entropy.
The maximum entropy criterion ensures that a continuous
distribution of diffusion coefﬁcients is obtained with no more
features than statistically warranted by the data14,21. In its most
straightforward implementation, the cFRAP model is ﬁtted to all
individual pixels in the recovery images. However, by averaging
the spatial information in rectangular rings, we found that the
same precision was obtained with a reduction of the calculation
time by about three orders of magnitude (cfr. Supplementary
Fig. 2 and Supplementary Note 1). Following optimization of the
relevant experimental parameters (Supplementary Figs 3 and 4,
and Supplementary Notes 2 and 3), we found from simulations
that cFRAP can distinguish two subpopulations if their diffusion
coefﬁcient differs by as small as a factor 3 (Supplementary Fig. 5a
and Supplementary Note 4). In comparison, in classic FRAP
where only the average ﬂuorescence in the bleach area is
considered as a function of time, the diffusion coefﬁcient of
both subpopulations should differ by at least a factor of 8
(Supplementary Fig. 5b and Supplementary Note 4). Next, we
conﬁrmed through simulations that cFRAP can correctly analyse
polydisperse systems with a continuous broad range of diffusion
coefﬁcients (Supplementary Fig. 6 and Supplementary Note 5).
Furthermore, we investigated what is the minimal signal to noise
ratio that is needed in the recovery images to perform meaningful
cFRAP analysis. Based on simulated data as well as experimental
data on a dilution series of ﬂuorescein isothiocyanate (FITC)-
dextran of 40 kDa (FD40), we found that cFRAP analysis can be
performed down to signal to noise ratio¼ 2.4 (Supplementary
Fig. 7). For FD40 this corresponded to a lower concentration limit
of 4 mgml 1 (100 nM) on the microscope used in this study.
The performance of cFRAP-sizing was compared experimen-
tally to dynamic light scattering (DLS) as a standard technique for
measuring the size distribution of nanomaterial dispersions.
Solutions of dextrans of various molecular weights were prepared
and their size distribution was measured by DLS. FITC-labelled
dextrans of similar molecular weights were used for sizing by
cFRAP. In all cases the cFRAP size distributions corresponded
very well with the ones obtained by DLS (Supplementary Fig. 8).
As could be expected, thanks to including spatial information in
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the cFRAP model, the polydispersity index (PDI) of the
distributions was signiﬁcantly less compared with the
apparent PDI measured by DLS which only takes time
information into account and, therefore, has more limited
precision (Supplementary Fig. 9).
Next, we wanted to prove experimentally that cFRAP is very
well capable of analysing broad size distributions of nano-
materials. Therefore, as a ﬁnal validation step, we prepared
mixtures of FITC-dextran (FD) with a gradually increasing range
of MW to see if cFRAP can measure the full-size distribution
correctly. As the results in Fig. 2 show, cFRAP can accurately
retrieve the expected size distributions from B2 to B80 nm,
in line with the aim to develop a method for nanomaterial
sizing in this range.
Characterization of protein aggregation in biological ﬂuids.
As a ﬁrst application, we used cFRAP-sizing to analyse protein
aggregates in the sub 0.1 mm range in full serum (Fig. 1). This is of
current interest since protein aggregation has emerged as a key
issue underlying multiple deleterious effects in the use of protein
therapeutics, including loss of efﬁcacy, altered pharmacokinetics,
reduced stability and shelf life, and induction of unwanted
immunogenicity7,8. Fluorescently labelled bovine serum albumin
(BSA) was used as a model protein, which could be analysed
by cFRAP down to a concentration of 4 mgml 1 (60 nM;
Supplementary Fig. 10). Protein aggregates were prepared by
applying heat stress to the BSA monomers in a buffer solution.
The unstressed and heat-stressed samples were ﬁrst characterized
in buffer solution by two standard techniques: DLS and size
exclusion chromatography (SEC). For the heat-stressed
sample, SEC showed both a monomer peak and the presence
of aggregates (Fig. 3a). However, the SEC signal corresponding
to aggregates was not very well resolved, so that the extent of
aggregation was difﬁcult to assess. On the other hand, DLS does
show the size range of aggregates in the heat-stressed sample but
failed to detect the monomers (Fig. 3b). Interestingly,
cFRAP-sizing could discriminate both monomers and
aggregates in a single measurement instead (Fig. 3c), with the
size range of aggregates in excellent agreement with the DLS size
distribution. This nicely demonstrates again the superior
resolving power of cFRAP. Next, we addressed the main
question if cFRAP is able to size protein aggregates directly in
serum, which is difﬁcult, if not impossible, to do by DLS or SEC.
cFRAP was used to analyse samples prepared of BSA monomers
and BSA aggregates in 90% serum. Comparison with the size
distributions in buffer solution shows that both monomers and
aggregates could be correctly sized in serum by cFRAP (Fig. 3d).
We conclude that cFRAP-sizing is very well capable of accurately
quantifying protein aggregates in a complex biological ﬂuid like
serum in the o0.1 mm range with excellent resolving power.
Assessing intestinal permeability in mice with septic shock. To
further evaluate the potential of cFRAP-sizing, we wondered to
which extent cFRAP could be suitable for a detailed assessment
of the permeability of the intestinal barrier in mice (Fig. 1).
The intestinal barrier is essential to prevent entry of the harmful
intestinal content into the bloodstream. It consists of a single
layer of epithelial cells that are sealed by tight junctions composed
of claudins and other proteins in the junctional complex. Loss of
intestinal barrier integrity is associated with various diseases, such
as sepsis and inﬂammatory bowel disease. As there are indications
that restoring intestinal integrity might ameliorate disease
progression22, there is great interest in ﬁnding pharmacological
compounds, such as probiotics, that can safely strengthen the
intestinal barrier. Therefore, methods are needed to accurately
and quantitatively assess the intestinal barrier permeability.
Inert ﬂuorescently labelled dextrans of different molecular sizes
(3 2,000 kDa) can be used for this purpose. A probe of a
particular size is administered orally and the quantity that leaks
into the blood is measured by ﬂuorimetry, potentially coupled to
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Figure 1 | Schematic overview of cFRAP-sizing experiments. (a) Measuring protein aggregates in serum and (b) measuring the permeability of the small
intestines and vasculature of mice following oral gavage or intravenous (IV) injection of ﬂuorescent probes. (c) Only a few microliters of sample are
required for cFRAP experiments on a standard confocal microscope (d) for retrieving the size distribution.
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size exclusion chromatography23. To get information to which
extent the barrier is compromised, this approach requires
administering dextrans of various sizes sequentially—for which
a new set of animals may be needed each time—and even then
only discrete size information is obtained depending on the
size of the probes used. In addition, these probes typically show
some polydispersity so that the exact size that has leaked through
is never certain.
To overcome these limitations, we propose the oral intake of a
mixture of FDs covering a wide range of sizes. cFRAP can then be
used to analyse the size distribution of FDs that have entered into
the blood circulation after permeation through the intestinal
barrier. A mixture of FD was prepared with a size ranging from
B2–80 nm. We veriﬁed that the entire size distribution could be
measured by cFRAP, both in PBS buffer and in serum (Fig. 4a).
The FD mixture was administered by oral gavage to mice
treated with an intraperitoneal injection of PBS (control) or
lipopolysaccharides (LPS) to induce septic shock. As
schematically shown in Fig. 4b, blood was collected by cardiac
puncture, respectively, 7 and 20 h after induction of septic shock
and plasma was prepared. In each case, oral gavage of FDs was
done 5 h before blood collection. Plasma ﬂuorescence was
measured by ﬂuorimetry to determine the overall fraction of
intestinal FD that had entered into the blood circulation
(Supplementary Fig. 11). These results conﬁrm that septic shock
results in loss of intestinal barrier integrity, as would be
expected24,25. cFRAP-sizing was subsequently performed on the
plasma samples to determine the size distribution of FDs
that had leaked through the epithelium (Fig. 4b). An exemplary
cFRAP experiment is shown in Supplementary Fig. 12 and
Supplementary Movie 1. To correct for differences in
concentration and molecular brightness between the various
FDs in the mixture, all size distributions in serum were
normalized to the reference measurement of the FD mixture in
PBS buffer (Fig. 4a). As for the control mice with intact intestinal
barrier (treated with PBS only), the amount of FD in plasma was
insufﬁcient to perform meaningful cFRAP experiments. In
LPS treated mice we found that at 7 h after LPS injection FDs
in the lower size range (up to 10 nm) had entered into the
blood circulation. Twenty hours after LPS injection the
distribution had not substantially changed, which suggests that
the barrier integrity does not change noticeably from 7 to 20 h
after inducing septic shock. Note that subtle differences in the
distributions may arise from the fact that the results at each time
point are determined from a different set of animals.
To validate these results, we performed extra experiments
according to the classical approach of administering FDs of
different size separately in different mice and measuring the
resulting ﬂuorescence by ﬂuorimetry in blood. In correspondence
with the cFRAP experiments, we found that only FD with a
nominal hydrodynamic size of B2.4 nm (FD4) or B4.0 nm
(FD10) had entered the blood circulation, while larger FDs were
not detected (Fig. 4c). Importantly, whileB30 mice were needed
to determine the size cut-off of the intestinal barrier by the
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classical method of using different FD probes sequentially,
microliter blood samples of only six mice were needed when
cFRAP-sizing was used. This ﬁvefold reduction in the number of
lab animals is one of the great advantages of cFRAP-sizing to
measure barrier leakiness in vivo.
Assessing vascular permeability in mice with septic shock.
Vascular permeability is essential for supplying tissues with
nutrients and clearing waste products. Vascular permeability may
be increased by diseases such as inﬂammatory disorders and
cancer, as well as by wound healing. This hyperpermeable state is
believed to inﬂuence the composition of the extravasate and
the pathways that solutes follow in crossing the vascular
endothelium26. Vascular hyperpermeability may also affect the
barriers in the brain, including the endothelial blood–brain (BBB)
and epithelial blood–CSF barrier (BCSFB)27. Disruption of the
integrity of the blood–brain barrier and blood–CSF barrier is
believed to play a detrimental role in disease pathogenesis as
protection of the delicate microenvironment of the brain from
neurotoxic agents in the blood is compromised.
To quantify the size range of molecules that can leak through
the vascular barrier, ﬂuorescently labelled dextrans of different
sizes can be injected intravenously, followed by analysis of
ﬂuorescence intensity in the relevant tissues (Fig. 1). According to
the classic protocol, each size of dextran is to be injected
separately, each time in a different animal. Instead, by
intravenous administration of a mixture of FDs covering a broad
range of sizes, here we demonstrate that a single experiment is
sufﬁcient when combined with cFRAP-sizing. First we conﬁrmed
that the full FD size range could be analysed in various
organ ﬂuids and CSF collected from control mice to which the
FD mixture was added (Supplementary Fig. 13). Next, as
schematically shown in Fig. 5, mice were treated with an
intraperitoneal injection of PBS (control) or LPS (septic shock).
The mixture of FDs was injected intravenously 1 h before sample
collection, which occurred, respectively, 7 and 20 h after PBS or
LPS injection. CSF was collected using the cisterna magna
puncture method. Kidney, brain, lung, spleen, ileum and liver
were isolated after cardiac perfusion with PBS/heparin to remove
all blood. Next, organ ﬂuid was extracted from the different
organs and total ﬂuorescence was measured by ﬂuorimetry after
removing cellular debris, showing that there was a large increase
in vascular permeability following septic shock (Supplementary
Table 1). From 7 to 20 h, the permeability increased further for
CSF, kidneys, lung and ileum. Next, these samples were analysed
with cFRAP to determine the size distribution of FDs that had
leaked through the vascular barrier. The size distributions (Fig. 5)
were normalized to the relative ﬂuorescence intensity as
measured by ﬂuorimetry (cfr. Supplementary Table 1) so that
the y-axis reﬂects the amount of FD that has leaked through
relative to the control (healthy PBS injected mice) for CSF or each
organ. The cFRAP-sizing results are shown in Fig. 5 for CSF and
kidney extract, while Supplementary Fig. 14 shows the cFRAP
results obtained on extracts from brain, lungs, spleen, ileum and
liver. Clearly, while no FD was found in the CSF of healthy
control mice, FDs with a size below B10 nm signiﬁcantly
permeated from the blood into the CSF in LPS treated mice. In
kidneys the endothelium was found to become more permeable
over time with FDs up toB20 nm leaving the blood and entering
the kidneys. Also here it is of note that 5 times less animals were
needed as would have been the case for the classic ﬂuorimetry
method for which the size probes are to be administered
separately in different animals. At the same time unprecedented
detailed information is obtained on the continuous size range of
probes that can leak through the barrier.
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Figure 3 | Sizing protein aggregates by cFRAP in comparison with SEC and DLS. Aggregates of ﬂuorescently labelled BSA were prepared through heat-
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cFRAP while the dashed lines indicate the s.d. on three independent repeats (with 10 cFRAP measurement per repeat). The size distributions as determined by
cFRAP in serum nicely correspond to those in buffer. This demonstrates that cFRAP is very well capable of analyzing protein aggregates in (nearly undiluted)
serum.
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Discussion
FRAP has been used for decades to measure the average diffusion
coefﬁcient of ﬂuorescently labelled molecules in various media,
from cells and extracellular matrices to food products and drug
delivery materials28. Instead, rather than measuring a single
average diffusion coefﬁcient, we succeeded in extracting the full
distribution of diffusion coefﬁcients from the recovery images
using a dedicated theoretical framework that makes use of the full
temporal and spatial information available in confocal recovery
images. By doing so we achieve a substantially improved size
resolution as explicitly demonstrated in Supplementary Fig. 2
and Supplementary Fig. 5, in comparison with ‘standard’ FRAP
analysis where the ﬂuorescence signal is integrated over the entire
bleach area so that only time information on the recovery is
taken into account18. As the cFRAP method is compatible with
standard laser scanning confocal microscopes, it is easily
accessible and straightforward to apply. Although cFRAP surely
can be used to perform detailed biophysical diffusion studies,
instead we have evaluated this technique to measure the size of
nanomaterials in biological ﬂuids. Considering the capabilities of
typical confocal microscopes in terms of sensitivity and image
acquisition rate, cFRAP is perfectly suited to measure the
diffusion of nanomaterials in the 1–100 nm size range in ﬂuids.
As such it nicely complements the ﬂuorescence single particle
tracking method that was recently developed in our group
for nanoparticle sizing primarily in the 0.1–1 mm range17,29.
A rectangular bleach area was chosen since for this geometry a
full analytical solution is available that describes the recovery
process both in time and space without any constraints on the
size of the bleach by taking into account all the necessary
parameters like the effective bleach resolution, the imaging
resolution, and so on ref. 30. This model, originally developed for
measuring single-component diffusion, was implemented here in
the maximum entropy method (MEM) framework to extend
its capability to analyse (semi-)continuous distributions of
diffusion coefﬁcients. By employing the full tempo-spatial
information in confocal recovery images, we have shown that
cFRAP offers better precision than techniques only using
diffusion time information like DLS or the classic FRAP
methods. Indeed, the PDI of size distributions of dextrans
measured by cFRAP was signiﬁcantly less compared with DLS.
While also ﬂuorescence correlation spectroscopy has been used to
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measure the size distribution of ﬂuorescently labelled compounds,
one can expect the same limited precision as for DLS as it also
only deals with the time information from the diffusion process
similar to DLS (ref. 31). When characterizing protein aggregation,
we even found that a single cFRAP experiment produces the same
size information as obtained by DLS and SEC combined.
Furthermore, a major beneﬁt of cFRAP is that microliter
samples are sufﬁcient. In principle even smaller volumes are
very well possible since a single confocal image series typically
probes a volume of 100 mm 100mm 10 mm which corresponds
to 0.1 nl. Assuming 10 measurements per sample this amounts to
a probed volume of only 1 nl. Sizing by cFRAP, therefore, is
perfectly compatible with miniaturization approaches like
microﬂuidics.
As a ﬁrst proof-of-concept application, we successfully
demonstrated that cFRAP-sizing can be used to characterize
protein aggregates directly in undiluted serum. This would be
impossible to do by DLS due to strong light scattering by serum
components. Also SEC is not without its problems since the high
serum protein content may lead to interactions with the column
matrix and altered elution proﬁles. Evidently the use of cFRAP
comes at the expense of having to label the protein of interest.
Yet, this is balanced by the fact that there are virtually no other
techniques at this moment to characterize submicrometer protein
aggregates in complex biological ﬂuids.
Based on cFRAP-sizing we also devised a new approach to
rapidly assess the integrity of the intestinal and vascular barriers
which is related to disease pathogenesis. While disruption of tight
junctions involved in cell cell contact causes leakage of small
molecules, the presence of epithelial apoptosis will allow
permeation of larger molecules as well32. In the classic
approach inert probes, such as FDs, of a particular size are
administered to lab animals. However, as the sequential
administration and ﬂuorimetric analysis of probes of different
sizes requires each time a different set of animals, it is
time-consuming, expensive and poses ethical issues. Instead, we
have demonstrated the use of a single mixture of probes (FDs)
covering a very broad range of sizes. After sample collection of
the relevant ﬂuids, a single cFRAP experiment on a microliter
sample can reveal the full-size distribution of probes that have
permeated through the barrier. The cFRAP-sizing method,
therefore, reveals in a single experiment the full-size
distribution of probes that can leak through the barrier.
Importantly, ﬁve times less animals were needed as compared
with the classic ﬂuorimetric method where FDs of (ﬁve) different
sizes would have to be administered and analysed separately.
Although there is one report that has tried to assess endothelial
barrier permeability with a mixture of FITC dextrans and
ﬂuorescence SEC analysis33, cFRAP-sizing has the clear
advantage of being able to work with tiny sample volumes,
even down to nanoliters if required. It is also very fast and does
not require calibration (other than an intrinsic viscosity
measurement) as is needed for SEC to interpret the elution
proﬁles. Using cFRAP-sizing we even succeeded in analysing
FD leakage in microliter samples of cerebrospinal ﬂuid,
notwithstanding that the ﬂuorescence was very weak. To the
best of our knowledge this would be impossible to do by SEC.
We conclude that sizing by cFRAP is a powerful and valuable
new analytical technique for measuring the size of nanomaterials
in complex biological ﬂuids. While we have demonstrated its
usefulness in proof-of-concept applications, the potential of
cFRAP-sizing reaches much further and more valuable
applications are expected to follow suit, potentially in
combination with microﬂuidic approaches which enable accurate
handling of small sample volumes.
Methods
Theory of cFRAP. We start from the rectangle FRAP (rFRAP) model developed
before for measuring a single average diffusion coefﬁcient according to Deschout
et al.,30 which makes use of both time and spatial information in the recovery
images:
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where t is the time after photobleaching, K0 the photobleaching parameter
(which determines the extent of bleaching), D is the isotropic diffusion coefﬁcient
of diffusing species, lx and ly are the width and height of the rectangular
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Figure 5 | Assessing the vascular permeability in mice. Following the induction of septic shock by intraperitoneal injection of LPS, a mixture of FDs
covering a broad size range (grey line) was intravenously injected, respectively, 6 h and 19 h after the LPS treatment. CSF and organs were collected
respectively at 7 h (green lines) and 20 h (orange lines) after the LPS treatment. cFRAP-sizing was performed on (a) CSF and (b) kidney-extract. Control
mice were injected with PBS (instead of LPS) to determine the leakage in healthy mice as a reference (black lines). Note that in healthy mice FDs did not
appear in the CSF. The data shown are average values obtained on 3 mice, with 10 cFRAP-sizing measurements per mouse. The solid lines are the average
of all these results, while the dashed lines indicate the corresponding standard deviation. Note that the Relative FI values can only be compared for the
various time points per ﬂuid. Comparison of relative FI values should not be made between different sample types.
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photobleaching area, and r2 is the mean square resolution of the bleaching and
imaging point-spread function. In case of N independent diffusing components, we
can simply make a superposition of the individual ﬂuorescence recovery proﬁles:
F x; y; tð Þ ¼
X
i
aieiFi x; y; tð Þ ð2Þ
where ai is the relative fraction of the ith component and ei is the corresponding
relative ﬂuorescence brightness. Evidently,
PN
i¼1 ai ¼ 1.
Deﬁning:
ki ¼ aieiK0i ð3Þ
the multicomponent rFRAP model becomes:
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The multicomponent rFRAP model of equation (4) can be generalized to describe a
continuous distribution of diffusion coefﬁcients a(D):
F x; y; tð Þ ¼
Z
a Dð Þf x; y; t;D;K0 Dð Þ; r Dð Þð ÞdD ð5Þ
where f(x, y, t, D, K0(D), e(D), r(D)) describes the ﬂuorescence recovery of a
component with diffusion coefﬁcient D. Inserting equations (1) and (2) into
equation (5) yields:
F x; y; tð Þ ¼ F0  F04
Z
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where f 0(x, y, t, D, r(D)) is deﬁned as:
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For numerical computation according to the MEM we now make the transition to
the semi-continuous case. Let D be discretized in n components (for example, with
equal interval in log(D) space) in the range of Dmin to Dmax, equation (7) becomes:
F x; y; tð Þ ¼ F0  F04
Xn
i¼1
kif
0 x; y; t;Di; rið Þ ð8Þ
where we made use of equation (3). Equation (8) can be used for direct ﬁtting to
the pixel values in the recovery images.
Alternatively, the recovery data can be analysed based on the average intensities
in ring areas (Supplementary Fig. 1b). This considerably reduces computation
time while retaining the essential spatial information, as shown in Supplementary
Note 1. The average intensity in ring Ri is calculated as:
Fi tð Þ ¼ 1Mi
X
ðx; yÞERi
Fðx; y; tÞ ð9Þ
where F(x, y, t) is deﬁned in equation (8) and Mi is the number of pixels inside
ring Ri .
Instead of performing a standard least-squares ﬁtting of equation (9) to the
experimental data, the MEM ﬁnds the ‘best-ﬁt’ solution with maximum entropy.
MEM ensures that the ﬁtting result (that is, the distribution of diffusion
coefﬁcients) contains the least possible information to avoid over-interpretation of
noise due to limited sampling statistics. In other words, it looks for the smoothest
best-ﬁt solution in the maximum entropy sense. The ‘historic MEM’ approach was
implemented in this work, which means maximizing the Shannon-Jaynes entropy:
S ¼ 
Xn
i¼1
kilogki ð10Þ
under the least-squares condition of w2¼M, where M is the total number of data
points. For the pixel based ﬁtting, the w2 statistic is calculated by:
w2 ¼
X
i
X
j
X
k
½Fij tkð Þ F0ij tkð Þ2
s2ijðtkÞ
ð11Þ
where Fij(tk) is the normalized ﬂuorescence at position xi, yj at time point tk and
sij2(tk) is the corresponding variance. F 0 ij(tk) is the corresponding theoretical value
calculated from equation (8).
On the other hand, for the ring analysis, the w2 statistic is calculated by:
w2 ¼
X
i
X
k
½Fi tkð Þ F0i tkð Þ2
s2i ðtkÞ
ð12Þ
where Fi(tk) is the experimental average ﬂuorescence in ith ring at time point tk and
si2(tk) is the corresponding variance. F 0 i(tk) is again the corresponding theoretical
value calculated from equation (9). The variance can be calculated for simulated
images according to:
s2i ðtkÞ ¼
s2
Mi
ð13Þ
where s is the s.d. on the pixel values used for simulating the FRAP recovery
images. For experimental images it can be calculated from ref. 34:
s2i ðtkÞ ¼
aFiðtkÞþ b
Mi
ð14Þ
Where a and b are constant parameters that can be determined by a series of
images with various laser intensities of a homogeneous ﬂuorescent solution with
identical instrumental settings as in the ﬁnal FRAP experiment35.
Based on the theory outlined above, a Matlab code was written for MEM analysis
of the recovery images which results in a semi-continuous distribution of diffusion
coefﬁcients, which can be converted to a distribution of sizes by the Stokes-Einstein
equation when required. The Matlab code source is online available36 and a user’s
guide is also available37. To ensure proper use of this method, it is important to stress
two important experimental requirements. The theory is based on 2D diffusion only.
In 3D extended samples (as is the case in this work) this means that bleaching should
be performed with an objective lens of sufﬁciently low numerical aperture (typically
o0.5) which produces a cylindrical laser beam in a substantial area above and below
the focal plane. In that case, the bleaching will be quite uniform over an extended
region along the optical axis, so that only 2D radial diffusion effectively takes
place38. Second, in the derivation of the rFRAP model according to Deschout et al.30,
the assumption is made of a linear photobleaching process. In reality, however,
photobleaching rather follows an exponential type of decrease. This means that the
model will only work perfectly for modest bleach depths, that is, up to 50%
photobleaching as demonstrated before30. This can be easily accommodated for by
changing the bleach laser intensity appropriately.
FRAP equipment and experimental procedure. FRAP experiments were per-
formed on a C1-si confocal microscope (Nikon, Japan) equipped with a 488 nm
Ar-ion laser of 40mW and acoustic optical tunable ﬁlter to modulate the laser
intensity for bleaching and imaging (fastest imaging rate B0.5 frame per sec).
Rectangular areas were photobleached and the ﬂuorescence recovery was imaged
using the Nikon NIS Elements AR software package. A  10 numerical aperture
0.45 plan apochromat objective lens was used for bleaching and imaging. The laser
power was adjusted to obtain 25–50% bleaching, in accordance with the theoretical
requirement of limited bleaching (due to the assumption of a linear photobleaching
process in the derivation of equation (1)). The recovery time depends on the
diffusion coefﬁcient as well as the size of the bleach area. A particular beneﬁt of our
theoretical framework is that we can adjust the size of the bleach rectangle in a
continuous fashion. The smallest component in our applications is FD of 4 kDa
(FD4), while the largest is FD of 500 kDa (FD500). To capture the diffusion from
the smallest to largest components we used a bleach area of 50 mm with a sampling
time that starts at 0.5 s per frame and increases to 16 s per frame towards the end of
the time-lapse recording. As explained in detail in Supplementary Note 3 this
ensures that the sampling was optimal over the entire experiment to capture the
fastest and slowest component in one and the same measurement.
For FRAP experiments, 4 ul of the samples was ‘sandwiched’ between a
microscope slide and a coverslip sealed by an adhesive spacer of 120 mm thickness
(Secure-seal, Spacer, Molecular probes, Leiden, The Netherlands; Fig. 1). This
provides a 3D environment for diffusion while avoiding ﬂow in the sample. All
FRAP measurements were performed at room temperature (22.5 C).
Simulation of FRAP images. FRAP images were simulated using equation (2) in
Matlab. Simulations were performed with the reported values of the diffusion
coefﬁcient(s) Di, their relatively frequency ai, photobleaching amount K0,i and
resolution parameter ri.
Viscosity measurement. The measured distribution of diffusion coefﬁcients can be
converted to a corresponding distribution of hydrodynamic sizes (diameter), using the
Stokes-Einstein equation D¼ kT/3pZd, where k is the Boltzmann constant, T the
absolute temperature, Z the dynamic viscosity of the solution and D the diffusion
coefﬁcient of the molecule. However, this requires accurate knowledge of the viscosity
of the sample. While, for example, a capillary viscosity metre can be used for this in
case of solutions prepared in the lab, it cannot be applied to the often minute samples
retrieved from animal experiments. Therefore, we have made use of a viscosity probe
with known size that can be added to the samples to inherently calibrate the viscosity
of the sample under study. 10 kDa FD (FD10) at a weight concentration of
20mgml 1 was added to the sample solution at a volume ratio of 1:20 so that the
effect on the sample viscosity by adding the viscosity probe was considered neglectable.
cFRAP data analysis. Before ﬁtting of the data to the cFRAP model, the recovery
data (Supplementary Fig. 1) was normalized to the ﬂuorescence before
bleaching. Normalization to the pre-bleach intensity can be performed by dividing
every pixel in the recovery images by the corresponding pixel in the pre-bleach
image. To limit the corresponding ampliﬁcation of noise, the pre-bleach image was
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smoothed ﬁrst with a median ﬁlter with a kernel of 5 5 pixels. Correction for
laser ﬂuctuations and bleaching during imaging is performed by dividing the pixels
of each recovery image by the average value from one reference background region
in the same image (Supplementary Fig. 1a). The reference background region was
placed sufﬁciently far from the bleach region so as to remain unaffected by the
diffusion front during the observation time.
Data analysis is done by ﬁtting of the cFRAP model (equation (8)) to the pixel
values of the normalized recovery images. Alternatively, as detailed in
Supplementary Note 1, the region of interested can be divided into n equally spaced
ring-shaped areas. In that case equation (9) is ﬁtted to the average intensity values
in each of the ring-shaped areas. The MEM was included into the analysis so as to
obtain the smoothest distribution fulﬁlling the requirement of w2¼M, where M is
the total number of data points used for ﬁtting. This is a well-known method to
ensure that the ﬁnal distribution does not contain more features than statistically
warranted by the data14. In practice, using the function ‘fmincon’ in the Matlab
Optimization tool box (The matworks, Natick, MA, USA) the entropy criterion
according to equation (10) was maximized, while the constraint w2¼M in
equation (12) was relaxed to the narrow interval M ﬃﬃﬃﬃﬃﬃﬃ2Mp  w2  Mþ ﬃﬃﬃﬃﬃﬃﬃ2Mp .
Covalent protein labelling with an extrinsic ﬂuorophore. A 10mgml 1 solu-
tion of BSA was prepared by dissolving BSA lyophilized powder Z96% (Sigma-
Aldrich) in carbonate buffer pH 8.3. The free amine groups of BSA were covalently
labelled by 5–6-carboxyﬂuoresceine succinimidyl ester (5(6) FAM, SE;
Life Technologies Corporation, Molecular Probes, Eugene, USA). For this purpose,
100ml of a 5mgml 1 ﬂuorescein solution in dimethylsulfoxide (Life Technologies
Corporation, Ghent, Belgium) was added to a 2ml 10mgml 1 BSA solution and
incubated for 1 h under constant gentle stirring. The incubation was stopped by
adding 200 ml of a 210mgml 1 hydroxylamine (Sigma-Aldrich; stop solution) in
ultrapure water adjusted to pH 8.5 with 4M sodium hydroxide solution
(Sigma-Aldrich). Next, the excess of free ﬂuorescein labels was removed by dialysis
overnight against 4 L 0.1M phosphate pH 7.0 in a Slide-a-lyser 20 kDa MWCO
(Thermo Scientiﬁc, Rockford, USA). The phosphate buffer was adjusted to pH by
varying the amount of 0.1M monobasic dihydrogen phosphate (WR, Leuven,
Belgium) and 0.1M dibasic monohydrogen phosphate (Merck, Darmstadt,
Germany) solution. The buffer was ﬁltered through a 0.2 mm PES ﬁlter (Novolab,
Geraardsbergen, Belgium) before use.
Soluble protein concentration and labelling efﬁciency was determined by
measuring the absorbance at 280 nm and at 495 nm respectively on a Spectramax
M2 (Molecular devices, Sunnyvale, USA) with the SoftMax pro software version
6.1. For all measurements, samples were diluted 10-fold and 200ml samples and
buffer controls were transferred in triplicate to a 96-well plate (96-well pureGrade,
non-sterile, transparent, F-bottom, Novolab).
The degree of labelling was calculated using the measured absorbance of the dye
at its absorbance maximum of 495 nm (blank corrected) and according to the
following equation:
DOL ¼ Amaxdye MWprotein
Cprotein  edye
with MWprotein for the molecular weight of the protein, edye for the molar
extinction coefﬁcient of the dye (68000 cm 1M 1) at its absorbance maximum
(494 nm) and Cprotein is the protein concentration (mgml 1). The Lambert-Beer
law is used to calculate the protein concentration. For this application, the
measured protein absorbance at 280 nm was corrected for the dye absorbance at
280 nm according to manufactures’ instructions using the following equation:
Aprotein¼A280 nm–Amax dye(CF) with CF ¼ A280 freedyeAmax freedye .
Dynamic light scattering size measurements. DLS size measurements were
performed on a Malvern Zetasizer Nano ZS (Malvern Instruments Ltd., Malvern,
UK) equipped with a 632 nm, 4mW He-Ne laser source. Instrument performance
was veriﬁed by a system suitability test according to the manufacturer’s IQ/OQ
documentation and consisting of a measurement of 60 and 200 nm polystyrene
beads from Thermo Scientiﬁc (Erembodegem, Belgium). For each measurement,
40ml samples were transferred into a ZEN0040 Micro cuvette (Malvern Instruments
Ltd.). Sample measurements were performed at 25 C with automatic attenuation.
Samples were equilibrated for 180 s at 25 C. Measurement position was ﬁxed at 4.65
by ‘The seek for optimum position’ option. The sample was measured 10 times using
automatic measurement duration with a delay of 60 s between each measurement.
Measurements were performed under a 173 backscattering angle. For data
processing, the general purpose algorithm was used. The PDI was deﬁned as
PDI¼ (s/d)2, where s is the s.d. of the size distribution and d the mean diameter.
Size exclusion chromatographic measurements. The protein size distribution in
the non-stressed and stressed samples for labelled and non-labelled BSA
was further evaluated by size exclusion chromatography. For chromatographic
separation, a Yarra SEC-3000 column (300mm 4.6mm 3.0 mm) attached
to a Security cartridge GFC 3000 (4 3.0mm) (Phenomenex, Utrecht, The
Netherlands) was installed on an Acquity H-Class UPLC BioSystem (Waters,
Milford, MA, USA) equipped with a PDA detector with a 5mm 1500 nl titanium
ﬂow cell. Empower 2 was used as operating system. The mobile phase consisted of
0.1M phosphate pH 7.0 and the used Gel Filtration Standard was from Bio-Rad
(Temse, Belgium). Before injection of the sample and standards on the column, the
insoluble aggregates were removed by centrifugation in a 5424R centrifuge with
FA-45-24-11 rotor (Eppendorf) for 10min at 15,000 r.p.m. The concentration of
the soluble protein was determined on a spectramax M2 multi-detection reader
using the Lambert-Beer equation with the measured absorbance at 280 nm and the
theoretical absorbance at 280 nm for a 1% solution (being 0.66 for BSA). In
addition, the absorbance at 320 nm was measured for background correction.
During analysis, the autosample tray and column oven sample tray were both
thermostated at 22 C. The ﬂow rate was set on 0.35mlmin 1. After equilibration
with the mobile phase, samples and standards were injected in triplicate. 20 mg was
injected for each sample. Protein elution from the column was detected at 280 nm,
while 320 nm was recorded as background control. The molecular weight standard
was injected in triplicate. For the proteins within the molecular weight separation
range of the column, a linear correlation between logarithm of the molecular
weight and the elution time was established and used for size estimation of the
aggregated and non-aggregated proteins.
Temperature stressed protein. Labelled and non-labelled BSA was diluted
10-fold to obtain a 1mgml 1 solution. Next, the sample was distributed over
1.5ml Eppendorf tubes (Eppendorf, Hamburg, Germany) in 1ml fractions and
subjected to temperature stress on incubation in a Thermomixer comfort
(Eppendorf) for 6 h at 75 C. A non-stressed labelled and non-labelled sample was
retained at 4 C. During all manipulations over the different steps, the samples were
kept protected from light.
To measure the size distribution of protein in biological ﬂuids, blood was
withdrawn on citrate from healthy volunteers under informant consent. Plasma
was prepared by centrifugation. For analysis of proteins with the cFRAP method,
mixtures of plasma and protein (90/10, v/v plasma/protein) were prepared. The
same dilutions of protein in buffer were made to serve as a control.
Fluorescent/dextran probes. FD or dextran (D) of various molecular weight
(MW) (FD4/D4: MW¼ 4 103 gmol 1, FD10/D10: MW¼ 1 104 gmol 1,
FD40/D40: MW¼ 4 104 gmol 1, FD150/D150: MW¼ 1.5 105 gmol 1,
FD500/D500: MW¼ 5 105 gmol 1) were purchased from Sigma-Adrich
(Bornem, Belgium). For the validation experiments of cFRAP, FD solutions were
prepared in HEPES buffer at pH 7.0 and dextran solutions were prepared in distilled
water. The concentration was always 0.5mgml 1 for DLS measurements. For each
type of FD, a concentration series was prepared to determine the linear ﬂuorescence
range as observed on the confocal microscope. For the in vivo permeability
measurements, different FDs were mixed at a weight ratio (FD4:FD10:FD40:FD150:
FD500¼ 40:25:15:10:10) and subsequently dissolved in PBS buffer, where the
concentration of FD4 was 80mgml 1. While this is outside the linear ﬂuorescence
range, such a high concentration was chosen to compensate for the dilution that
occurs when the mixture is injected into mice.
Animals. C57BL/6J mice were housed in an SPF animal facility with ad libitum
access to food and water. Both male and female mice (8–12 weeks old) were used.
All experiments were approved by the ethics committee of the Faculty of Science of
Ghent University. Mice were distributed randomly in different cages and mice
from the same cage were randomly allocated to different experimental
groups. They were injected intraperitoneally (i.p.) with 8.75mg kg 1 body weight
LPS from Salmonella enterica serotype abortus equi (Sigma), an LD100 dose for
wild-type C57BL/6J mice. No statistical method was used for sample size estimate.
In vivo experiments on intestinal permeability. Control mice (injected with
D-PBS) were sampled 7 h after injection. Septic shock mice were sampled 7 and
20 h after induction of peripheral inﬂammation. FITC-labelled dextran solution
was administered to mice by gavage 5 h before sampling. Blood obtained by heart
puncture was collected in EDTA-coated tubes (Sarstedt) and plasma was prepared.
Leakage of FITC-labelled dextran into the circulation was determined by
measurement of the ﬂuorescence with lex/lem¼ 488/520 nm. Values were nor-
malized to the PBS control value. After ﬂuorescence measurement, these samples
were also measured by cFRAP in a similar fashion as for the vascular permeability
experiments. No blinding was done for all of samples. The ﬂuorescence intensity of
these samples as measured by ﬂuorimetry were compared by one-way analysis of
variance. No samples or animals were excluded from the analysis
In vivo experiments on vascular permeability. Control mice (injected with
D-PBS) were sampled 7 h after injection. Septic shock mice were sampled 7 and
20 h after induction of peripheral inﬂammation. One hour before sampling, mice
were injected intravenously (IV) with the relevant FITC-labelled dextran solutions.
CSF was harvested from the fourth ventricle, centrifuged at 300g to remove all cell
debris, and cerebrospinal ﬂuid (CSF) supernatant was collected and diluted 50-fold
in D-PBS (Invitrogen) before analysis. Next, mice were transcardially perfused with
D-PBS supplemented with heparin to remove all labelled dextran in circulation.
Organs were isolated, cut into small pieces and incubated with formamide to
extract the remaining FITC-labelled dextran from the tissues. After overnight
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incubation at 37 C, samples were centrifuged and supernatant was collected.
Finally, the ﬂuorescence of CSF and organ supernatant was measured at lex/
lem¼ 488/520 nm by Fluostar Omega and values were normalized to the PBS
control per tissue. Again, the samples of the ﬂuorescence were compared by one-
way analysis of variance. The samples were subsequently analysed by cFRAP to
determine the size distribution of FDs in the various bodily ﬂuids and organs.
Data availability. Data supporting the ﬁndings of this study are available within
the article and its Supplementary Information Files. The Matlab source code and a
user guide are available for download36,37.
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